Genmab's epcoritamab combo cuts lymphoma progression risk by 60%

June 29, 2026 4:14 PM

Genmab A/S (Nasdaq: GMAB) announced topline results from the Phase 3 EPCORE DLBCL-4 trial showing that epcoritamab combined with lenalidomide ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found